Human Immunodeficiency Virus (HIV) Epidemiology Forecast to 2025 Risk Factors and Global Trends

Human Immunodeficiency Virus (HIV) Epidemiology Forecast to
2025 Risk Factors and Global Trends
“The Humman Immunodeficiency Virus (HIV) EpiCast Report provides an
overview of the risk factors and global trends for HIV in the nine major
markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Brazil, and
China).
Human immunodeficiency virus (HIV) is a lentivirus that impairs and destructs the CD4 cells of the immune
system. This weakens the immune system, leaving an infected individual more susceptible to other illnesses
and, over time, impairing the individual's ability to fight off infections.
Epidemiologists utilized national and international HIV and AIDS databases, surveillance data, and robust peerreviews journal articles to build the forecast of total prevalent and diagnosed prevalent cases of HIV in the 8MM.
HIV is defined as an infection with HIV, regardless of the stage of disease. This corresponds to the International
Classification of Diseases 10th edition (ICD-10) code B20.
Diagnosed prevalent cases of HIV were segmented by age and sex using country-specific data, whenever
available; when data were not available, appropriate proxies were used. For Japan, Epidemiologists provided an
alternative forecast for the 20-year diagnosed prevalent cases of HIV, which better aligns with the ART market
sales data after consolidation. Epidemiologists also provide an alternative forecast for Japan in the EpiCast
model based on the reported prevalent HIV cases.
Browse Detail Market Report With TOC @ http://www.hexareports.com/report/epicast-reporthuman-immunodeficiency-virus-hiv-epidemiology-forecast-to-2025
Follow Us:
Epidemiologists forecast that the total prevalent cases of HIV in the 8MM will increase from 3,632,410 in 2015
to 4,266,548 in 2025 at an Annual Growth Rate (AGR) of 1.75%. The US will have the highest number of total
prevalent cases of HIV in both 2015 and 2025 at 1,315,263 and 1,514,925, respectively. Epidemiologists forecast
that the diagnosed prevalent cases of HIV in the 8MM will increase from 2,926,335 in 2015 to 3,616,811 in 2025
at an AGR of 2.36%. In Japan, Epidemiologists forecast the 20-year diagnosed prevalent cases of HIV to increase
from 20,438 in 2015 to 25,417 in 2025 at an AGR of 2.44%.
Scope of this Report:



The Humman Immunodeficiency Virus (HIV) EpiCast Report provides an overview of the risk factors and
global trends for HIV in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, Brazil,
and China). For the 8MM (US, France, Germany, Italy, Spain, UK, Brazil, and China) it also includes a 10-year
epidemiological forecast for the total prevalent cases of HIV (both sexes and all ages), and diagnosed
prevalent cases of HIV segmented by sex and age from 2015-2025. The diagnosed prevalent cases of HIV
are further segmented into those receiving antiretroviral therapy (ART), those with hepatitis B virus (HBV)
co-infection, and those with hepatitis C virus (HCV) co-infection. For Japan, GlobalData epidemiologists
provide a 10-year forecast for the 20-year diagnosed prevalent cases of HIV segmented by sex and age from
2015-2025. The 20-year diagnosed prevalent cases of HIV are further segmented into those receiving ART,
those with HBV co-infection, and those with HCV co-infection.
The HIV epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of
disease trends in the 9MM.
Request A Sample copy of This Report @ http://www.hexareports.com/report/epicast-reporthuman-immunodeficiency-virus-hiv-epidemiology-forecast-to-2025/request-sample
Reasons To Buy
The HIV EpiCast report will allow you to 1. Develop business strategies by understanding the trends shaping and driving the global HIV market.
2. Quantify patient populations in the global HIV market to improve product design, pricing, and launch plans.
3. Organize sales and marketing efforts by identifying the age groups and sex that present the best
opportunities for HIV therapeutics in each of the markets covered.
4. Understand co-infection population and ART treated population for HIV patients.
Explore Related Reports:
 United States Computed Tomography (CT) Systems Market to 2022
http://www.hexareports.com/report/united-states-contrast-media-injectors-market-outlook-to-2022
Follow Us:
 United States Contrast Media Injectors Market Outlook to 2022
http://www.hexareports.com/report/united-states-contrast-media-injectors-market-outlook-to-2022
 United States Magnetic Resonance Imaging (MRI) Systems Market Outlook to 2022
http://www.hexareports.com/report/united-states-magnetic-resonance-imaging-mri-systems-marketoutlook-to-2022
About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom
research and consulting services to a host of key industries across the globe. We offer comprehensive
business intelligence in the form of industry reports which help our clients obtain clarity about their
business environment and enable them to undertake strategic growth initiatives.
Contact Information:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Our Website: http://www.hexareports.com/
Follow Us:

Human Immunodeficiency Virus EpiCast Report provides an overview of the risk factors and global trends of industry in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan).

Download Report